1. Wiesenberg, I., Chiesi, M., Missbach, M.,
Spanka, C., Pignat, W. and Carlberg, C. Specific activation of the
nuclear receptors PPARg and RORA by the antidiabetic thiazolidinedione BRL
49653 and the antiarthritic thiazolidinedione derivative CGP 52608. (1998)
Mol. Pharmacol. 53, 1131-1138 (Impact factor1998
5.4).
PDF-FILE
2. Lörper, M., Clairmont, A., Carlberg, C. and Sies, H.
Identification of two activating elements within the proximal promoter
region of the human GST-A1 and -A2 genes. (1998) Arch. Biochem. Biophys.
359, 122-127 (Impact factor1998 2.5).
PDF-FILE
3. Quack, M., Mørk Hansen, C., Binderup, E., Kissmeyer, A.-M. and
Carlberg, C. Metabolism of the vitamin D3 analogue EB1089 alters
receptor complex formation and reduces promoter selectivity. (1998) Br.
J. Pharmacol. 125, 607-614 (Impact factor1998 3.7).
PDF-FILE
4. Danielsson, C., Fehsel, K., Polly, P. and Carlberg, C.
Differential apoptotic response of human melanoma cells to
1a,25-dihydroxyvitamin D3 and its analogues. (1998) Cell Death Diff.
5, 946-952 (Impact factor1998 4.0).
PDF-FILE
5. Quack, M., Clarin, A., Binderup, E., Björkling, F., Mørk Hansen, C
and Carlberg, C. Structural variants of the vitamin D analogue
EB1089 reduce its ligand sensitivity and promoter selectivity. (1998) J.
Cell. Biochem. 71, 740-750 (Impact factor1998 2.8).
PDF-FILE
6. Quack, M., Szafranski, K., Rouvinen, J. and Carlberg, C. The
role of the T-box for function of the vitamin D receptor on different types
of response elements. (1998) Nucl. Acid Res. 26, 5372-5378 (Impact
factor1998 4.9). PDF-FILE |
|
|
|
